Find Academic Supervisors

Steven G. ClarkeView profile

Professor

• Biochemistry
• Systems Biology
• Biological Regulation
• +8 more

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

Shweta AgarwalView profile

Clinical Professor

• Pathology
• Head and Neck Pathology
• Cytopathology
• +3 more

Shweta Agarwal is a board-certified clinical pathologist specializing in Head and Neck pathology and Cytopathology. Currently affiliated with Mayo Clinic in Jacksonville, Florida, she focuses on diagnosing salivary gland, thyroid, oral cavity, and sinonasal cancers. Her research integrates artificial intelligence for metastasis prediction and explores PD-L1 expression in rare tumors. 2018 Fellowship in Cytopathology - University of California San Francisco Medical Center 2017 Fellowship in Head and Neck Pathology - Massachusetts General Hospital 2016 Residency in Anatomic Pathology - University of Oklahoma Health Sciences Center 2011 Senior Residency in Oncopathology - Tate Memorial Hospital 2003 MBBS - GSVM Medical College, Kanpur University Her research bridges clinical pathology with computational tools, investigating salivary gland cancers, thyroid neoplasms, and oral squamous cell carcinoma. Key publications include AI-driven nodal metastasis predictions and PD-L1 analysis in rare cancers. Scientific awards include the 2025 Mayo Clinic 'Healing' recognition, 2022 Presidential Teaching Fellow nomination, and multiple best paper awards. She serves on committees for the College of American Pathologists and Papanicolaou Society of Cytopathology.

G. Petur NielsenView profile

Professor

• Bone and Soft Tissue Pathology
• Molecular Genetics of Bone Tumors
• Chordoma Research
• +5 more

G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms

Torsten NielsenView profile

Professor

• Sarcoma
• Breast Cancer
• Molecular Diagnostics
• +7 more

Professor Torsten Nielsen is a clinician-scientist at the University of British Columbia 's Department of Pathology & Laboratory Medicine (Faculty of Medicine), based at Vancouver General Hospital and BC Cancer . He directs UBC's MD/PhD Program , contributes to cancer clinical trials with the Canadian Cancer Trials Group , and chairs the international Connective Tissue Oncology Society 's Research Committee. Key affiliations: UBC, Vancouver General Hospital, BC Cancer, Molecular and Advanced Pathology Core Academic focus: Translational research in sarcomas and breast cancer His research prioritizes translating genomic discoveries into clinical diagnostics and treatments, particularly for synovial sarcoma , breast cancer subtypes , and tenosynovial giant cell tumors . He develops FDA-cleared molecular assays like the PAM50 (Prosigna) test and leads pan-Canadian precision oncology initiatives . Collaborative efforts include work with Stanford, Leiden, and DKFZ Heidelberg. Recent publications highlight advancements in epigenetic therapies , immune biomarker validation , and synovial sarcoma pathogenesis . His lab's work on CSF1/CSF1R signaling inspired new treatment strategies for joint-destructive tumors. Scientific Awards: Fellow, Canadian Academy of Health Sciences Fellow, Royal Society of Canada As director of UBC's MD/PhD Program, he trains future clinician-scientists. His lab team includes experts in epigenomics , proteomics , and mouse modeling . Current projects focus on precision oncology for sarcomas and Ki67 standardization in breast cancer.

Lu LinView profile

Assistant Professor

• Epilepsy
• Women's Health
• Critical Care EEG Monitoring
• +3 more

Dr. Lu Lin is an Assistant Professor in the Department of Neurology - Neurophysiology at Baylor College of Medicine. His primary clinical and research interests focus on epilepsy, women's health, critical care EEG monitoring, and drug-resistant epilepsy management. He holds certifications in Epilepsy, Clinical Neurophysiology, and Neurology from the American Board of Psychiatry and Neurology. Dr. Lin's educational background includes an MD from Peking University Health Science Center and a PhD from the University of Texas Southwestern Medical Center. His clinical training includes residencies at UT Southwestern and fellowships at Harvard Medical School affiliates in neurology and clinical neurophysiology. His research explores EEG abnormalities in critical care settings, mechanisms of drug-resistant epilepsy, and molecular aspects of genetic disorders like Rothmund-Thomson syndrome. Notable recent work includes studies on EEG biomarkers in severe neurological conditions and iPSC modeling of genetic diseases. Dr. Lin is an active member of professional organizations including the American Academy of Neurology and American Epilepsy Society. His work bridges clinical neurophysiology with translational research in genetic disorders and neurological complications of systemic illnesses.

Jianhua RuanView profile

Professor

• Bioinformatics
• Computational Systems Biology
• Machine Learning for Life Sciences
• +7 more

Dr. Jianhua Ruan is a Professor in the Department of Computer Science at The University of Texas at San Antonio (UTSA), affiliated with the College of Sciences. He holds a Ph.D. in Computer Science from Washington University in St. Louis and has been a faculty member at UTSA since 2007. His research focuses on bioinformatics, computational systems biology, and machine learning applied to life sciences. Specific areas include modeling cis-regulatory networks, analyzing biological networks via graph algorithms, and biomarker discovery using omics data. Dr. Ruan collaborates extensively with biologists at UTSA and the UT Health Science Center on genomic, transcriptomic, proteomic, and epigenomic studies. Key research interests include: Machine learning for cis-regulatory network modeling Graph algorithms for biological network analysis Integrated omics data analysis for disease prediction Epigenetic regulation and cancer biology His work has been supported by NIH, NSF, and the San Antonio Life Sciences Institute. Notable achievements include a Best Performer award in the DREAM Reverse Engineering Challenges (2008) and the UTSA Faculty Research Award (2007). Dr. Ruan organizes the UTSA Computer Science Graduate Research Seminar, fostering interdisciplinary collaboration. He has developed software tools like TSCAN for single-cell RNA-seq analysis and contributes to computational methods for biomarker discovery and network-based classification.

Stephen RamseyView profile

Associate Professor

• Computational Systems Biology
• Bioinformatics
• Precision Medicine
• +6 more

Stephen Ramsey, an Associate Professor at Oregon State University, holds dual appointments in the School of Electrical Engineering and Computer Science (College of Engineering) and the Department of Biomedical Sciences (Carlson College of Veterinary Medicine). With a PhD in Physics from the University of Maryland, his postdoctoral training in computational genomics at the University of Washington, and professional experience at the Institute for Systems Biology and Center for Infectious Disease Research, Ramsey bridges computational methods with biomedical applications. Education : Ph.D., Physics, University of Maryland; M.S., Physics, University of Maryland; Sc.B., Mathematical Physics, Brown University Ramsey specializes in computational systems biology , focusing on bioinformatics , biomedical knowledge graphs , and precision medicine . His research integrates machine learning , gene regulatory network modeling , and multi-omics data analysis to address challenges in rare disease diagnostics , drug monitoring , and inflammatory disease mechanisms . Current work includes AI-driven biomedical translation and electrochemical biosensor development for non-invasive diagnostics . Recent publications highlight knowledge graph applications in translational biomedicine , causal network inference in clinical-environmental data integration , and cross-species cancer transcriptomics . His team develops tools like RTX-KG2 and PloverDB to standardize biomedical data sharing and semantic reasoning . Scientific Awards : 2019 Zoetis Award (Carlson College of Veterinary Medicine) 2016 NSF CAREER Award 2016 PhRMA New Investigator Award 2010 NIH K25 Mentored Quantitative Research Award Ramsey advises in computational biology courses (CS 446/546) and contributes to biomedical AI through projects like mediKanren for rare disease diagnostics . His NSF-funded research explores gene expression noise and regulatory network dynamics , while NIH and PhRMA grants support his translational medicine initiatives. He leads the Ramsey Laboratory , which develops graph-based reasoning tools for biomedical data translation and multi-omics integration . The lab's work spans comparative oncology models, electrochemical biosensors , and knowledge graph infrastructure for clinical decision support .

Sugandha BhatiaView profile

Research Fellow

• Cancer Biology
• Epithelial-Mesenchymal Transition
• Chromosomal Instability
• +4 more

Dr. Sugandha Bhatia is a Postdoctoral Research Fellow at Queensland University of Technology (QUT), working within the Faculty of Health and School of Biomedical Sciences. Her research primarily focuses on cancer biology, particularly examining epithelial-mesenchymal transition, chromosomal instability, and tissue engineering applications for cancer treatment and bone regeneration. Dr. Bhatia completed her PhD in Cancer Biology at Queensland University of Technology. Her doctoral research laid the foundation for her current work on cellular plasticity in cancer progression and treatment resistance. Dr. Bhatia's research interests center on understanding the mechanisms of cancer progression, with particular emphasis on: Epithelial-mesenchymal transition (EMT) and its role in cancer metastasis Chromosomal instability and aneuploidy in cancer development Tissue engineering approaches for bone regeneration post-cancer treatment Mechanisms of chemoresistance in breast and lung cancers Metabolic reprogramming during cancer cell state transitions Her publication record demonstrates a strong focus on the intersection of cancer biology, cellular plasticity, and therapeutic interventions. Dr. Bhatia has published extensively in high-impact journals such as Trends in Pharmacological Sciences, Acta Biomaterialia, and Cancers, with her work frequently exploring how cellular state transitions influence cancer progression and treatment response. Dr. Bhatia actively collaborates with researchers across multiple institutions and disciplines, contributing to interdisciplinary projects that bridge basic cancer biology with clinical applications. Her work on tissue-engineered bone constructs shows promise for improving outcomes following osteosarcoma resection. As a Postdoctoral Research Fellow, Dr. Bhatia contributes to research training and mentoring of graduate students working on related projects, particularly in the areas of cancer cell biology and tissue engineering.

Floris FoijerView profile

Professor

• Cancer Biology
• Genetic Instability
• Cell Cycle Control
• +5 more

Prof. Floris Foijer is a Full Professor at the University of Groningen's Faculty of Medical Sciences and UMCG, leading the Laboratory of Genomic Instability in Development and Disease. His research focuses on the consequences of aneuploidy in cancer, particularly how cancer cells exploit genomic instability for survival and proliferation. He holds roles as Director of the UMCG Functional Genomics Centre and Program Leader at the Kolff Institute's 'Regenerate' program. Foijer obtained his PhD from the Netherlands Cancer Institute (2006) and completed postdoctoral training at Harvard Medical School (2007-2009) and the Wellcome Trust Sanger Institute (2009-2011). He has pioneered murine models for chromosomal instability and developed CRISPR-based technologies. Key research areas include genomic instability's role in cancer evolution, therapeutic vulnerabilities in aneuploid cancers, and the link between chromosomal instability and aging. His work has been recognized with prestigious awards, including the Vici Grant (2023) and EMBO Fellowship (2009). Foijer collaborates internationally, contributing to projects like the ERIBA/iPSC/CRISPR facility supporting genome editing research. His lab's findings have advanced understanding of aneuploidy-driven cancer mechanisms and potential targeted therapies. Scientific Awards: - Vici Grant (2023) - EMBO Long-Term Postdoctoral Fellowship (2009) - Dutch Cancer Society Postdoctoral Fellowship (2007) Grants and Activities: - Director of UMCG Functional Genomics Centre (iPSC/CRISPR facility) - Member of KWF Assessment Board and Genomic Integrity Centre Scientific Board - Supervised 17 PhD/Master’s theses (noted in his profile) Labs/Teams: - Laboratory of Genomic Instability in Development and Disease - ERIBA/iPSC/CRISPR facility collaborations

• Molecular Pathology
• Cancer Research
• Osteosarcoma
• +7 more

Claudio Di Cristofano is an Associate Professor of Pathology at Sapienza University of Rome, Department of Medical-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine. He serves as President of the Master's Degree in Medicine and Surgery at the Latina campus and as Vice President of School of Medicine E. His teaching responsibilities span multiple programs including Medicine and Surgery, Nursing and Midwifery Sciences, Dental Hygiene, and Physiotherapy. Dr. Di Cristofano completed his medical education at Sapienza University of Rome in 1994 and obtained his Board in Pathology from the University of Ferrara in 2001. His professional journey includes positions at Santa Chiara University Hospital of Pisa (2002-2007) and San Camillo-Forlanini Hospital in Rome (2001) before joining Sapienza University of Rome in 2008. His research focuses on molecular mechanisms of carcinogenesis and neoplastic progression, with particular emphasis on osteosarcoma, kidney pathology, breast cancer, and soft tissue tumors. He utilizes advanced molecular techniques including laser microdissection (LCM), fluorescence in situ hybridization (FISH), and tissue microarrays (TMA) to identify potential therapeutic targets in solid tumors. A significant research strand involves investigating nucleocytoplasmic trafficking of proteins through subcellular localization and immunohistochemical methods. Analysis of his recent publications reveals a strong focus on translational pathology, with research spanning cancer biomarkers, molecular diagnostics, obesity-related metabolic disorders, and NAFLD pathogenesis. His work demonstrates consistent integration of basic science with clinical applications across multiple organ systems. Dr. Di Cristofano maintains active membership in numerous professional societies including the International Academy of Pathology (IAP), United States Canadian Academy of Pathology (USCAP), European Society of Pathology, and several specialized Italian pathology groups focusing on molecular pathology, uropathology, dermatopathology, and hematopathology. He has received multiple research grants from Sapienza University since 2008, focusing on pancreatic cancer, osteosarcoma, breast cancer, and molecular pathology approaches. His academic output includes 64 international papers, 2 national papers, 4 scientific books, and 2 teaching books, with a total impact factor of 171,248 and an H-index of 22. Dr. Di Cristofano maintains research laboratory facilities at the ICOT Hospital in Latina, where he conducts his pathological research alongside his clinical and teaching responsibilities. His office hours are held in Latina on Wednesdays (9:00-11:00) and in Rome (Pathological Anatomy, ground floor) on Thursdays (14:00-16:00).

• Retinoblastoma
• Retinal Development
• Cancer Biology
• +3 more

David E. Cobrinik serves as Associate Professor of Research in Ophthalmology and Cancer Biology at the University of Southern California, with primary laboratory affiliation at Children's Hospital Los Angeles (CHLA). His research program investigates retinal development mechanisms and their relationship to ocular diseases, with specialized focus on retinoblastoma pathogenesis and novel diagnostic approaches. Dr. Cobrinik's research centers on the cellular origins of retinoblastoma, where his laboratory established that cone photoreceptor precursors serve as the tumor cell-of-origin. His work demonstrates how cone-specific signaling pathways collaborate with pRB loss to drive tumorigenesis, revealing new therapeutic targets. Current investigations focus on three key areas: (1) developmental signaling pathways that sensitize retinal cells to Rb loss; (2) molecular events converting normal retinal cells to malignant retinoblastomas; and (3) targeting vulnerabilities in pRB-deficient cone precursor circuitry. Additionally, his team pioneers human pluripotent stem cell models to recreate retinal development in vitro, enabling unprecedented study of human retinal biology and disease mechanisms. Analysis of Dr. Cobrinik's publication record (2020-2024) reveals dominant themes in liquid biopsy development for retinoblastoma, particularly aqueous humor-based detection of tumor DNA and biomarkers. His laboratory has established clinical utility for aqueous humor liquid biopsy in diagnosis, prognosis, and treatment monitoring. Significant work also explores retinoblastoma's cellular origins in cone precursors and molecular mechanisms involving MYCN/MDM2 signaling, alongside stem cell-derived retinal organoid models for studying development and disease. Scientific Awards James S. McDonnell Foundation Scholar (1996-1999) Susan G. Komen Breast Cancer Foundation Postdoctoral Fellow (1992-1995) American Cancer Society Postdoctoral Fellow (1989-1992) American Cancer Society Joseph S. Silber Pre-doctoral Fellow (1983) Oscar E. Schotté Award for Biological Research, Amherst College (1982) Dr. Cobrinik mentors graduate students and postdoctoral researchers through USC's graduate programs and CHLA research initiatives. His work has been supported by major foundations including the James S. McDonnell Foundation and American Cancer Society, with current funding likely directed toward aqueous humor liquid biopsy development and retinal organoid modeling. Collaborative grants with the CHLA Vision Center enable translational research bridging basic science and clinical ophthalmology. Dr. Cobrinik leads research within the CHLA Vision Center, collaborating with ophthalmologists, oncologists, and stem cell biologists to advance retinal disease modeling. His laboratory specializes in retinal organoid systems and live imaging techniques to study cone photoreceptor maturation and tumorigenesis, maintaining close integration with clinical teams for rapid translation of discoveries to patient care.

Robert A. WeinbergView profile

Professor

• Cancer Biology
• Cancer Metastasis
• Cancer Stem Cells
• +3 more

Robert A. Weinberg is the Daniel K. Ludwig Professor for Cancer Research and a Core Member at the Whitehead Institute for Biomedical Research, affiliated with MIT. His research focuses on cancer metastasis, cancer stem cells, and molecular mechanisms underlying epithelial-mesenchymal transition (EMT). He holds a PhD (1969) and SB in Biology (1964) from MIT. Educations: PhD in Biology, MIT, 1969 SB in Biology, MIT, 1964 Research Interests: His work investigates how cancer cells metastasize, the role of EMT in cancer stem cell properties, and molecular regulators of metastasis. Key areas include understanding tumor microenvironment interactions, immunosuppressive mechanisms in breast carcinomas, and therapeutic resistance. Recent Publications Trends: Recent studies emphasize EMT's role in metastasis, cancer stem cell plasticity, and developing immunotherapies for ovarian cancer. He has identified critical genes (e.g., Twist, p63/p73) and pathways (e.g., GLIS2 signaling) driving metastatic colonization and therapeutic resistance. Awards & Honors: Japan Prize (2021) Salk Institute Medal (2016) Breakthrough Prize in Life Sciences (2013) Wolf Prize (2004) National Medal of Science (1997) Member of the National Academy of Sciences (1985) Advising & Grants: He has mentored numerous researchers and led grants focused on EMT, cancer stem cells, and metastasis. His work bridges molecular oncology with clinical applications in combination immunotherapy and targeted therapies. Labs & Collaborations: Led the Whitehead Institute's cancer biology group, collaborating on projects like genetically defined mouse models for ovarian cancer and CRISPR-based screens to identify metastasis regulators.

• Computational and Mathematical Biology
• Data Science
• Bioinformatics
• +3 more

Leili Shahriyari is an Associate Professor in the Department of Mathematics and Statistics at the University of Massachusetts Amherst . Her research focuses on developing computational frameworks that integrate machine learning, mathematical modeling, and statistical methods to advance personalized cancer therapies. Key initiatives include: Digital Twin Platforms: Creating patient-specific models like My Virtual Cancer to predict treatment responses for breast cancer and rare cancers like uveal melanoma. QSP Modeling: Enhancing quantitative systems pharmacology (QSP) approaches to personalize treatments using patient-specific data rather than generic datasets. TumorDecon Software: A Python package for deconvolving tumor cell composition, supported by NIH-NCI funding. Education: Ph.D. in Mathematics, Johns Hopkins University (2013) M.S.E. in Computer Science, Johns Hopkins University (2012) Research Themes: Computational and Mathematical Biology Data-Driven Oncology Cancer Microenvironment Modeling Collaborations: Her work intersects interdisciplinary teams in computational biology, bioinformatics, and clinical oncology to advance translational cancer research.

Abu Shameem Md. Saadat KhandakarView profile

Assistant Professor

• Molecular Biology
• Medical Biology
• Genetics
• +3 more

Abu Shameem Md. Saadat Khandakar is an Assistant Professor at the Department of Basic Medical Sciences, Faculty of Medicine, Gaziantep University (Türkiye). He holds a doctorate in Molecular Embryology from Tokyo Medical and Dental University (2012) and completed post-doctoral training at the University of Tokyo (2013-2014) and Tokyo Medical and Dental University (2012-2013). Research Focus: Molecular biology, transcriptional regulation (ARID3A/B and E2F pathways), non-coding RNA, cancer biology (osteosarcoma, breast cancer, NSCLC), stem cells, and epigenetics. Teaching: Courses in cellular physiology, molecular genetics, embryonic stem cells, gene therapy, scientific ethics, and advanced cytogenetics at undergraduate and graduate levels. Awards: Multiple fellowships including MEXT, Takase Foundation, and Hello Tomorrow Challenge Conference Fellowship. Projects: Investigated ARID3A/B interactions in osteosarcoma, phytochemical effects on cancer cells, and experimental models of premature ovarian insufficiency. His 15 recent publications include studies on lncRNA regulation in cancer, bacterial resistance mechanisms, and mitochondrial disease genetics. He serves on doctoral committees and has co-edited journals like Zeugma Biological Science .

Jorge Torres-MoraView profile

Physician Scientist

• Sarcoma Pathology
• Molecular Genetics
• Immunohistochemistry
• +4 more

Jorge Torres-Mora, M.D., is a pathologist at Mayo Clinic in Rochester, Minnesota, affiliated with the Department of Laboratory Medicine and Pathology and the Mayo Clinic College of Medicine. His work focuses on sarcoma pathology, molecular genetics, and immunohistochemical characterization of rare tumors. Specialized in bone and soft tissue pathology Active in molecular diagnostics and gene fusion analysis His research spans sarcoma genetics, including EWSR1::FLI1 and EWSR1::PATZ1 fusions, with recent publications in Modern Pathology and Mayo Clinic Proceedings . Key areas include: Molecular mechanisms in sarcomas Novel entity classification Immunohistochemical marker development Recent articles highlight his contributions to understanding: PRAME utility in melanoma mimics Hybrid morphology in peripheral nerve sheath tumors Head and neck sarcoma genetics Collaborative work includes teams at Mayo Clinic and international institutions. No explicit awards or student advisement details appear in the text.